Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial

Highlights • Phase I clinical trial of CIGB-247, a cancer therapeutic vaccine that uses modified VEGF as antigen. • The vaccine was safe and well tolerated. • CIGB-247 elicited specific B and T-cell immune responses. • Increasing antigen dose led to more seroconverted individuals with VEGF blocking ability and positive gamma-IFN ELISPOT. • Twelve of the thirty recruited patients have evidences of objective clinical benefit and two show complete responses.